The Board of Directors of Zydus Lifesciences Limited approved the unaudited financial results for the quarter and nine months ended December 31, 2025, at their meeting held on February 9, 2026. The company subsequently held its Q3FY26 post-results earnings call on February 10, 2026, pursuant to regulations 30 and 46(2)(oa) of the SEBI Listing Regulations.

Board Meeting and Regulatory Compliance

The meeting commenced at 11:10 a.m. and concluded at 1:15 p.m., with results reviewed by the Audit Committee and taken on record by the Board pursuant to Regulation 33 of SEBI Listing Regulations. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) and underwent limited review by statutory auditors Deloitte Haskins & Sells LLP.

Consolidated Financial Performance Q3FY26

The company demonstrated robust consolidated performance during Q3FY26. Total revenue from operations reached ₹68,645 million, representing significant 30.30% year-over-year growth from ₹52,691 million in Q3FY25. Net profit for the quarter stood at ₹10,421 million compared to ₹10,235 million in the corresponding quarter of the previous year, marking a 1.82% increase. EBITDA for the quarter stood at ₹18.20 billion, up 31% year-on-year with an EBITDA margin of 26.50%.

Business Segment Performance

North America Operations

The North America business, comprising the United States and Canada, registered revenues of ₹28,000 million during the quarter, up 16% year-on-year. The base US business continued to grow driven by sustained volume expansion and new products launched over the last 12 months. The company filed 18 ANDAs, received 8 approvals and launched 4 new products during the quarter. On the US specialty front, the company launched BEIZRAY (albumin-solubilized docetaxel injection), its first oncology 505(b)(2) product.

India Branded Formulations

The India branded formulation business sustained its growth trajectory with a robust 14% year-on-year growth, outperforming the market growth. The growth was driven by persistent traction in innovation products and pillar brands, with the chronic segment continuing to grow at a faster pace. Contribution of chronic portfolio increased to 45.30% as per IQVIA MAT December 2025.

International Markets and Consumer Wellness

International markets formulation business posted revenues of ₹7.90 billion with strong year-on-year growth of 38%. The Consumer Wellness business recorded revenues of ₹9.60 billion, up 113% year-on-year with full quarter consolidation of Comfort Click business.

Strategic Developments and Innovation Pipeline

During the earnings call, Managing Director Dr. Sharvil Patel highlighted key strategic developments. The company plans to file Saroglitazar Magnesium with the USFDA for PBC indication, marking a pivotal milestone for growth in the specialty pharmaceutical space. In January 2026, the company received final approval from the USFDA for Zycubo (copper histidinate), becoming the first and only therapy approved for the treatment of Menkes disease.

The company has licensed two large molecules, Pembrolizumab and Ranibizumab biosimilars, leveraging the recently acquired biologics manufacturing facility in the US. The company expects to launch Ranibizumab in the second half of the year and aims for meaningful Bio CDMO business development over the next 2-3 years.

Exceptional Items and Future Outlook

The quarter's results were affected by exceptional items totaling ₹849 million, primarily attributed to the one-time impact of New Labour Codes implementation. The company expects R&D expenses to remain at 7.50%-8.00% of revenue for FY26, with Q4 EBITDA margins expected to be 23% plus despite minimal Lenalidomide revenue.

Management expressed confidence in continued double-digit growth across key business segments, with the US generics business showing 11% volume growth and international markets expected to maintain 20% plus growth trajectory.

Source: Earnings Call Transcript

Zydus Lifesciences Limited has formally announced the superannuation of a key senior management personnel, marking a significant leadership transition within the pharmaceutical company. The announcement pertains to Mr. Manoj Kumar Kamra, who served as Senior Vice President-Corporate Affairs, and represents part of the company's ongoing compliance with regulatory disclosure requirements.

Superannuation Details

The company disclosed that Mr. Manoj Kumar Kamra has superannuated from his position as Senior Vice President-Corporate Affairs, with the cessation taking effect from the closing working hours of January 31, 2026. The superannuation represents a natural conclusion to his tenure in the senior management role.

Regulatory Compliance

The announcement was made in strict adherence to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure also references SEBI circulars dated November 11, 2024, and December 31, 2024, ensuring full compliance with the latest regulatory guidelines for senior management changes.

The formal communication was filed with both major stock exchanges where the company's shares are listed:

• BSE Limited (Code: 532321)
• National Stock Exchange of India Limited (Code: Zyduslife)

Corporate Governance

The disclosure was officially signed and submitted by Dhaval N. Soni, Company Secretary and Compliance Officer (Membership No. FCS7063), on January 31, 2026. The digital signature timestamp shows 16:59:37 +05'30', demonstrating the company's commitment to timely regulatory reporting.

The announcement includes comprehensive annexure details as required under the listing regulations, providing transparency regarding the nature and timing of the senior management change. This structured approach reflects the company's adherence to corporate governance standards and regulatory compliance protocols.